ASPMN® has several ways for you to support our organization ...
Benefactor Level - $7,500
Benefits Include:
-
Annual Corporate Spotlight in E-News, ASPMN®’s membership newsletter
-
Recognition on our website, newsletter and at prominently at our national conference
-
10% discount on one set of membership mailing labels annually
-
Corporate Advertisement on our website
-
Subscription to our Journal,
Pain Management Nursing and E-News newsletter
-
Annual meeting with our Board of Directors at our National Conference
-
Logo recognition throughout the conference location and exhibit hall
-
One complimentary conference registration
Supporter Level - $5,000
Benefits Include:
-
Recognition on our website, newsletter and at prominently at our national conference
-
10% discount on one set of membership mailing labels annually
-
Subscription to our Journal,
Pain Management Nursing and E-News newsletter
-
Annual meeting with our Board of Directors at our National Conference
Contributor Level - $1,500
Benefits Include:
-
Subscription to our Journal,
Pain Management Nursing and E-News newsletter
-
Annual meeting with our Board of Directors at our National Conference
To become an ASPMN® Corporate Sponsor,
click here.
ASPMN® would like to thank the following Corporate Members:
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
Helixmith Co., Ltd is a gene therapy company with over 20 years’ experience in this field. The company is based in Seoul and San Diego and publicly traded in the Korean stock market. Currently, the company is actively focusing on developing the proprietary plasmid DNA-based drug Engensis (VM202) for neurological and cardiovascular diseases including, but not limited to, painful diabetic peripheral neuropathy (DPN), diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), claudication, coronary artery disease (CAD), and Charcot-Marie-Tooth disease (CMT). Clinical trials are being conducted in the U.S., Korea, and China. The company also has an early phase pipeline in AAV-based gene therapy for neuromuscular diseases and CAR-T cell therapy for solid tumors.
